Results 131 to 140 of about 5,796 (217)

Ausência de escapes mutantes para o medicamento palivizumab® do Vírus Respiratório Sincicial Humano (hRSV) circulante, na cidade de São Paulo durante o ano de 2004. [PDF]

, 2008
Patrícia Alves Ramos Bosso
openalex   +1 more source

Respiratory syncytial virus immunization in children: The old, the new and what's just around the corner. [PDF]

Hum Vaccin Immunother
Paes BA, Bacchini F, Bracht M, Rodgers-Gray B, Carbonell-Estrany X.   +4 more
europepmc   +1 more source

WS19.8 Use of palivizumab to prevent respiratory syncytial virus (RSV) infection in cystic fibrosis. A 10 year retrospective review pre and post introduction of palivizumab prophylaxis in Northern Ireland

, 2013
Helen Groves, Laura Jenkins, Mary MacFarlane, A. Reid, Michael D. Shields   +4 more
openalex   +1 more source

Palivizumab and prevention of childhood respiratory syncytial viral infection: protocol for a systematic review and meta-analysis of breakthrough infections [PDF]

, 2019
Shelly Jun, Meghan Sebastianski, Robin Featherstone, Joan Robinson   +3 more
openalex   +1 more source

Cost-Effectiveness Analysis of Nirsevimab for the Prevention of Respiratory Syncytial Virus among Italian Infants. [PDF]

Clin Drug Investig
Bini C, Marcellusi A, Cazzato D, Muzii B, Soudani S, Bozzola E, Midulla F, Baraldi E, Bonanni P, Boccalini S, Orfeo L.   +10 more
europepmc   +1 more source

Challenges in the prophylaxis of severe respiratory syncytial virus infections. [PDF]

J Pediatr (Rio J)
Feitosa DC, Vieira SE.
europepmc   +1 more source

Direct Out-of-Pocket Costs of Nirsevimab <i>vs.</i> Palivizumab during the First Respiratory Syncytial Virus Season: A Comparative Analysis. [PDF]

Infect Chemother
Yun KW, Kang D.
europepmc   +1 more source

Estimating the economically justifiable price of nirsevimab versus standard of practice for the prevention of respiratory syncytial virus infections in neonates and infants in Spain: a cost-utility modelling study. [PDF]

BMJ Public Health
Gil-Prieto R, Pérez-Martín J, Díaz Aguiló A, Soudani S, Platero-Alonso L, López-Belmonte JL, de la Cuadra-Grande A, Casado MÁ, Álvarez Aldean J.   +8 more
europepmc   +1 more source

Palivizumab coverage rates among moderate-to-late preterm infants in Korea: a nationwide cross-sectional study. [PDF]

Epidemiol Health
Kim S, Lee S, Choe YJ, Heo JS.
europepmc   +1 more source

Palivizumab.

Indian pediatrics, 2002
D, Gupta, P, Gupta
openaire   +1 more source